Get started
IONIS PHARMACEUTICALS, INCIONIS PHARMACEUTICALS, INCIONIS PHARMACEUTICALS, INC

IONIS PHARMACEUTICALS, INC

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Forecast Seasonals Bonds

IONS chart


Full chart

IONS upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪122.53 B‬MXN
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−46.34MXN
Net income (FY)
‪−6.22 B‬MXN
Revenue (FY)
‪13.38 B‬MXN
Shares float
‪145.55 M‬
Beta (1Y)
0.46

Employees


Employees (FY)
927
Change (1Y)
+131 +16.46%
Revenue / Employee (1Y)
‪849.67 K‬MXN
Net income / Employee (1Y)
‪−395.13 K‬MXN

About Ionis Pharmaceuticals, Inc.


Sector
Health Technology
CEO
Brett P. Monia
Headquarters
Carlsbad
Website
ionis.com
Founded
1989
FIGI
BBG00PG3SJS8
Ionis Pharmaceuticals, Inc. engages in the development and commercialization of human therapeutic drugs using antisense technology. It operates through the Ionis Core segment. The Ionis Core segment exploits a novel drug discovery platform to generate a pipeline of drugs. The company was founded by Stanley T. Crooke, David J. Ecker, Christopher K. Mirabelli, and Brett P. Monia on January 10, 1989 and is headquartered in Carlsbad, CA.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—
‪0.00‬

Ideas



See all ideas 

IONS news



Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

IONS highest yielding bonds


IONS5835891
Ionis Pharmaceuticals, Inc. 1.75% 15-JUN-2028
Yield to maturity
1.43%
Maturity date
Jun 15, 2028
IONS5104819
Ionis Pharmaceuticals, Inc. 0.125% 15-DEC-2024
Yield to maturity
1.00%
Maturity date
Dec 15, 2024
IONS5397611
Ionis Pharmaceuticals, Inc. 0.0% 01-APR-2026
Yield to maturity
0.80%
Maturity date
Apr 1, 2026

Explore more bonds 

Frequently Asked Questions


Depending on the exchange, the stock ticker may vary. For instance, on BIVA exchange IONIS PHARMACEUTICALS, INC stocks are traded under the ticker IONS.
IONS stock has risen by 1.97% compared to the previous week, the month change is a 1.97% rise, over the last year IONIS PHARMACEUTICALS, INC has showed a 1.97% increase.
We've gathered analysts' opinions on IONIS PHARMACEUTICALS, INC future price: according to them, IONS price has a max estimate of 1,633.17 MXN and a min estimate of 736.92 MXN. Watch IONS chart and read a more detailed IONIS PHARMACEUTICALS, INC stock forecast: see what analysts think of IONIS PHARMACEUTICALS, INC and suggest that you do with its stocks.
IONS stock is 1.97% volatile and has beta coefficient of 0.46. Track IONIS PHARMACEUTICALS, INC stock price on the chart and check out the list of the most volatile stocks — is IONIS PHARMACEUTICALS, INC there?
Today IONIS PHARMACEUTICALS, INC has the market capitalization of ‪121.36 B‬, it has increased by 0.98% over the last week.
Yes, you can track IONIS PHARMACEUTICALS, INC financials in yearly and quarterly reports right on TradingView.
IONIS PHARMACEUTICALS, INC is going to release the next earnings report on Nov 6, 2024. Keep track of upcoming events with our Earnings Calendar.
IONS earnings for the last quarter are −8.25 MXN per share, whereas the estimation was −16.97 MXN resulting in a 51.35% surprise. The estimated earnings for the next quarter are −22.18 MXN per share. See more details about IONIS PHARMACEUTICALS, INC earnings.
IONIS PHARMACEUTICALS, INC revenue for the last quarter amounts to ‪4.13 B‬ MXN, despite the estimated figure of ‪2.86 B‬ MXN. In the next quarter, revenue is expected to reach ‪2.55 B‬ MXN.
IONS net income for the last quarter is ‪−1.22 B‬ MXN, while the quarter before that showed ‪−2.37 B‬ MXN of net income which accounts for 48.64% change. Track more IONIS PHARMACEUTICALS, INC financial stats to get the full picture.
No, IONS doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 2, 2024, the company has 927.00 employees. See our rating of the largest employees — is IONIS PHARMACEUTICALS, INC on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. IONIS PHARMACEUTICALS, INC EBITDA is ‪−6.28 B‬ MXN, and current EBITDA margin is −42.05%. See more stats in IONIS PHARMACEUTICALS, INC financial statements.
Like other stocks, IONS shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade IONIS PHARMACEUTICALS, INC stock right from TradingView charts — choose your broker and connect to your account.